Amylyx reports FY2025 net loss of $144.7M; avexitide Phase 3 enrollment complete, topline data Q3 2026

Amylyx Pharmaceuticals, Inc.

Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.
Phase 3 LUCIDITY trial of avexitide in PBH enrollment complete; topline data expected Q3 2026, potential launch 2027.
Cash, equivalents, and short-term investments $317.0M at Dec 31, 2025; cash runway into 2028.
R&D expenses decreased to $90.4M from $104.1M due to lower AMX0035 spending, offset by increased avexitide costs.
Selected AMX0318 (GLP-1 receptor antagonist) as development candidate for PBH; IND filing targeted 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.